Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma.

Kim, Heung Cheol; Suk, Ki Tae; Kim, Dong Joon; Yoon, Jai Hoon; Kim, Yeon Soo; Baik, Gwang Ho; Kim, Jin Bong; Kim, Chang Hoon; Sung, Hotaik; Choi, Jong Young; Han, Kwang Hyub; Park, Seung Ha
World journal of gastroenterology
2014Jan ; 20 ( 3 ) :745-54.
저자 상세정보
Kim, Heung Cheol - Heung Cheol Kim, Department of Radiology, Hallym University College of Medicine, Chuncheon 200-704, South Korea.
Suk, Ki Tae - Heung Cheol Kim, Department of Radiology, Hallym University College of Medicine, Chuncheon 200-704, South Korea.
Kim, Dong Joon - Heung Cheol Kim, Department of Radiology, Hallym University College of Medicine, Chuncheon 200-704, South Korea.
Yoon, Jai Hoon - Heung Cheol Kim, Department of Radiology, Hallym University College of Medicine, Chuncheon 200-704, South Korea.
Kim, Yeon Soo - Heung Cheol Kim, Department of Radiology, Hallym University College of Medicine, Chuncheon 200-704, South Korea.
Baik, Gwang Ho - Heung Cheol Kim, Department of Radiology, Hallym University College of Medicine, Chuncheon 200-704, South Korea.
Kim, Jin Bong - Heung Cheol Kim, Department of Radiology, Hallym University College of Medicine, Chuncheon 200-704, South Korea.
Kim, Chang Hoon - Heung Cheol Kim, Department of Radiology, Hallym University College of Medicine, Chuncheon 200-704, South Korea.
Sung, Hotaik - Heung Cheol Kim, Department of Radiology, Hallym University College of Medicine, Chuncheon 200-704, South Korea.
Choi, Jong Young - Heung Cheol Kim, Department of Radiology, Hallym University College of Medicine, Chuncheon 200-704, South Korea.
Han, Kwang Hyub - Heung Cheol Kim, Department of Radiology, Hallym University College of Medicine, Chuncheon 200-704, South Korea.
Park, Seung Ha - Heung Cheol Kim, Department of Radiology, Hallym University College of Medicine, Chuncheon 200-704, South Korea.
ABSTRACT
AIM: To evaluate the clinical characteristics of patients with Barcelona Clinic Liver Cancer (BCLC) stage 0 and A hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE).

METHODS: Between January 2001 and September 2011, 129 patients with BCLC stage 0 and stage A HCC who underwent TACE were retrospectively enrolled. Patient characteristics, routine computed tomography and TACE findings, survival time and 1-, 5-, and 10-year survival rates, risk factors for mortality, and survival rates according to the number of risk factors were assessed.

RESULTS: The mean size of HCC tumors was 2.4 짹 1.1 cm, and the mean number of TACE procedures performed was 2.5 짹 2.1. The mean overall survival time and 1-, 5-, and 10-year survival rates were 80.6 짹 4.9 mo and 91%, 63% and 49%, respectively. In the Cox regression analysis, a Child-Pugh score > 5 (P = 0.005, OR = 3.86), presence of arterio-venous shunt (P = 0.032, OR = 4.41), amount of lipiodol used (> 7 mL; P = 0.013, OR = 3.51), and female gender (P = 0.008, OR = 3.47) were risk factors for mortality. The 1-, 5-, and 10-year survival rates according to the number of risk factors present were 96%, 87% and 87% (no risk factors), 89%, 65%, and 35% (1 risk factor), 96%, 48% and unavailable (2 risk factors), and 63%, 17%, and 0% (3 risk factors), respectively (P < 0.001). CONCLUSION: TACE may be used as curative-intent therapy in patients with BCLC stage 0 and stage A HCC. The Child-Pugh score, arterio-venous shunt, amount of lipiodol used, and gender were related to mortality after TACE.
keyword
Carcinoma; Chemoembolization; Efficacy; Hepatocellular; Stage; Survival; Therapeutic
MESH
Aged, Carcinoma, Hepatocellular/mortality/pathology/radiography/*therapy, *Chemoembolization, Therapeutic/adverse effects, Chi-Square Distribution, Disease-Free Survival, Female, Humans, Kaplan-Meier Estimate, Liver Neoplasms/mortality/pathology/radiography/*therapy, Male, Middle Aged, Neoplasm Staging, Odds Ratio, Proportional Hazards Models, Retrospective Studies, Risk Factors, Sex Factors, Survival Rate, Time Factors, Tomography, X-Ray Computed, Treatment Outcome, Tumor Burden
링크

주제코드
주제명(Target field)
연구대상(Population)
연구참여(Sample size)
대상성별(Gender)
질병특성(Condition Category)
연구환경(Setting)
연구설계(Study Design)
연구기간(Period)
중재방법(Intervention Type)
중재명칭(Intervention Name)
키워드(Keyword)
유효성결과(Recomendation)
Patients with more than 2 risk factors should be treated by other curative-intent treatments after the first TACE.
연구비지원(Fund Source)
근거수준평가(Evidence Hierarchy)
출판년도(Year)
참여저자수(Authors)
대표저자
DOI
10.3748/wjg.v20.i3.745.
KCD코드
ICD 03
건강보험코드